Mifepristone Followed by Misoprostol Compared with Placebo Followed by Misoprostol as Medical Treatment for Early Pregnancy Loss (the Triple M trial): A Double-Blind Placebo-Controlled Randomised Trial

Background: Worldwide, millions of women seek treatment for early pregnancy loss (EPL) annually. Medical management with misoprostol is widely used, but only effective 60% of the time. Pre-treatment with mifepristone prior to misoprostol might improve the success rate of medical management. Methods:...

Full description

Saved in:
Bibliographic Details
Published in:Fertility & reproduction 2022-09, Vol.4 (3n04), p.99-99
Main Authors: HAMEL, Charlotte, COPPUS, Sjors, VAN DEN BERG, Joyce, HINK, Esther, VAN SEETERS, Jacoba, VAN KESTEREN, Paul, MERIEN, Ashley, TORRENGA, Bas, VAN DE LAAR, Rafli, VAN SCHELTINGA, Josien Terwisscha, GAUGLER-SENDEN, Ingrid, GRAZIOSI, Peppino, VAN RUMSTE, Minouche, NELISSEN, Ewka, VANDENBUSSCHE, Frank, SNIJDERS, Marcus
Format: Article
Language:English
Subjects:
KEYNOTE AND INVITED SPEAKER PRESENTATIONS
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Worldwide, millions of women seek treatment for early pregnancy loss (EPL) annually. Medical management with misoprostol is widely used, but only effective 60% of the time. Pre-treatment with mifepristone prior to misoprostol might improve the success rate of medical management. Methods: This was a multi-centre, double-blind, placebo-controlled randomised trial in 17 Dutch hospitals. Women with a non-viable pregnancy between 6 and 14 weeks of gestation were eligible for inclusion after at least one week of expectant management. Participants were randomised (1:1) between oral mifepristone 600 mg or an oral placebo tablet. Participants took 400 mg misoprostol orally, repeated after four hours on day two and, if necessary, day three. Primary outcome was expulsion of gestational sac and endometrial thickness
ISSN:2661-3182
2661-3174
DOI:10.1142/S2661318222740115